博瑞医药BGM1812注射液获得药物临床试验批准通知书

Core Viewpoint - 博瑞医药's subsidiary, 博瑞制药, has received approval from the National Medical Products Administration for clinical trials of BGM1812 injection for overweight or obesity treatment, marking a significant step in the company's development pipeline [1] Group 1 - 博瑞医药's BGM1812 injection has already received FDA approval for clinical trials in the United States, with the first patient enrolled [1] - As of the announcement date, there are no similar targeted therapies for weight loss approved for market globally [1]